Viking Therapeutics Inc (VKTX) Stock AnalysisVKTXViking Therapeutics Inc

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Viking Therapeutics is a good buy right now due to its current price of $28.51, which is significantly lower than the average analyst price target of $102, indicating a potential upside of over 250%. Additionally, the company has raised $575 million to fund its promising weight-loss drug VK2735, which is projected to capture a substantial share of the $200 billion obesity drug market by 2030. However, the main risk is the negative earnings trend, with a projected EPS of -1.10 for Q2 2026, which could impact investor sentiment if not addressed.

3 analysts cover VKTX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 97.00.